Global OTC Drug 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI12249947

Publication Date:

December 27, 2024

Pages:

131

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global OTC Drug market size was valued at US$ million in 2023. With growing demand in downstream market, the OTC Drug is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global OTC Drug market. OTC Drug are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of OTC Drug. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the OTC Drug market.
Non-prescription drugs refer to drugs that can be purchased for the convenience of the public without a prescription from a physician or other medical professional. The general public can use the drugs on their own discretion according to the drug labels and instructions.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on OTC Drug market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the OTC Drug market. It may include historical data, market segmentation by Type (e.g., Class A OTC Drug, Class B OTC Drug), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the OTC Drug market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the OTC Drug market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the OTC Drug industry. This include advancements in OTC Drug technology, OTC Drug new entrants, OTC Drug new investment, and other innovations that are shaping the future of OTC Drug.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the OTC Drug market. It includes factors influencing customer ' purchasing decisions, preferences for OTC Drug product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the OTC Drug market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting OTC Drug market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the OTC Drug market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the OTC Drug industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the OTC Drug market.
麻豆原创 Segmentation:
OTC Drug market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Class A OTC Drug
Class B OTC Drug
Segmentation by application
Hospital
Clinic
Household
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer HealthCare
GlaxoSmithKline(GSK)
Johnson&Johnson
Pfizer
Sanofi
AstraZeneca
BioGaia
Bristol Myers Squibb
Bukwang Pharmaceutica
Chr. Hansen
Cipla
CoLucid
Daiichi Sankyo
Friggs
DSM
Eisai
Eli Lilly
Herbalife
Euradite

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global OTC Drug 麻豆原创 Size 2019-2030
2.1.2 OTC Drug 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 OTC Drug Segment by Type
2.2.1 Class A OTC Drug
2.2.2 Class B OTC Drug
2.3 OTC Drug 麻豆原创 Size by Type
2.3.1 OTC Drug 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global OTC Drug 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 OTC Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Household
2.5 OTC Drug 麻豆原创 Size by Application
2.5.1 OTC Drug 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global OTC Drug 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 OTC Drug 麻豆原创 Size by Player
3.1 OTC Drug 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global OTC Drug Revenue by Players (2019-2024)
3.1.2 Global OTC Drug Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global OTC Drug Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 OTC Drug by Regions
4.1 OTC Drug 麻豆原创 Size by Regions (2019-2024)
4.2 Americas OTC Drug 麻豆原创 Size Growth (2019-2024)
4.3 APAC OTC Drug 麻豆原创 Size Growth (2019-2024)
4.4 Europe OTC Drug 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa OTC Drug 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas OTC Drug 麻豆原创 Size by Country (2019-2024)
5.2 Americas OTC Drug 麻豆原创 Size by Type (2019-2024)
5.3 Americas OTC Drug 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC OTC Drug 麻豆原创 Size by Region (2019-2024)
6.2 APAC OTC Drug 麻豆原创 Size by Type (2019-2024)
6.3 APAC OTC Drug 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe OTC Drug by Country (2019-2024)
7.2 Europe OTC Drug 麻豆原创 Size by Type (2019-2024)
7.3 Europe OTC Drug 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa OTC Drug by Region (2019-2024)
8.2 Middle East & Africa OTC Drug 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa OTC Drug 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global OTC Drug 麻豆原创 Forecast
10.1 Global OTC Drug Forecast by Regions (2025-2030)
10.1.1 Global OTC Drug Forecast by Regions (2025-2030)
10.1.2 Americas OTC Drug Forecast
10.1.3 APAC OTC Drug Forecast
10.1.4 Europe OTC Drug Forecast
10.1.5 Middle East & Africa OTC Drug Forecast
10.2 Americas OTC Drug Forecast by Country (2025-2030)
10.2.1 United States OTC Drug 麻豆原创 Forecast
10.2.2 Canada OTC Drug 麻豆原创 Forecast
10.2.3 Mexico OTC Drug 麻豆原创 Forecast
10.2.4 Brazil OTC Drug 麻豆原创 Forecast
10.3 APAC OTC Drug Forecast by Region (2025-2030)
10.3.1 China OTC Drug 麻豆原创 Forecast
10.3.2 Japan OTC Drug 麻豆原创 Forecast
10.3.3 Korea OTC Drug 麻豆原创 Forecast
10.3.4 Southeast Asia OTC Drug 麻豆原创 Forecast
10.3.5 India OTC Drug 麻豆原创 Forecast
10.3.6 Australia OTC Drug 麻豆原创 Forecast
10.4 Europe OTC Drug Forecast by Country (2025-2030)
10.4.1 Germany OTC Drug 麻豆原创 Forecast
10.4.2 France OTC Drug 麻豆原创 Forecast
10.4.3 UK OTC Drug 麻豆原创 Forecast
10.4.4 Italy OTC Drug 麻豆原创 Forecast
10.4.5 Russia OTC Drug 麻豆原创 Forecast
10.5 Middle East & Africa OTC Drug Forecast by Region (2025-2030)
10.5.1 Egypt OTC Drug 麻豆原创 Forecast
10.5.2 South Africa OTC Drug 麻豆原创 Forecast
10.5.3 Israel OTC Drug 麻豆原创 Forecast
10.5.4 Turkey OTC Drug 麻豆原创 Forecast
10.5.5 GCC Countries OTC Drug 麻豆原创 Forecast
10.6 Global OTC Drug Forecast by Type (2025-2030)
10.7 Global OTC Drug Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Bayer HealthCare
11.1.1 Bayer HealthCare Company Information
11.1.2 Bayer HealthCare OTC Drug Product Offered
11.1.3 Bayer HealthCare OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Bayer HealthCare Main Business Overview
11.1.5 Bayer HealthCare Latest Developments
11.2 GlaxoSmithKline(GSK)
11.2.1 GlaxoSmithKline(GSK) Company Information
11.2.2 GlaxoSmithKline(GSK) OTC Drug Product Offered
11.2.3 GlaxoSmithKline(GSK) OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 GlaxoSmithKline(GSK) Main Business Overview
11.2.5 GlaxoSmithKline(GSK) Latest Developments
11.3 Johnson&Johnson
11.3.1 Johnson&Johnson Company Information
11.3.2 Johnson&Johnson OTC Drug Product Offered
11.3.3 Johnson&Johnson OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Johnson&Johnson Main Business Overview
11.3.5 Johnson&Johnson Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer OTC Drug Product Offered
11.4.3 Pfizer OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Sanofi
11.5.1 Sanofi Company Information
11.5.2 Sanofi OTC Drug Product Offered
11.5.3 Sanofi OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Sanofi Main Business Overview
11.5.5 Sanofi Latest Developments
11.6 AstraZeneca
11.6.1 AstraZeneca Company Information
11.6.2 AstraZeneca OTC Drug Product Offered
11.6.3 AstraZeneca OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 AstraZeneca Main Business Overview
11.6.5 AstraZeneca Latest Developments
11.7 BioGaia
11.7.1 BioGaia Company Information
11.7.2 BioGaia OTC Drug Product Offered
11.7.3 BioGaia OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 BioGaia Main Business Overview
11.7.5 BioGaia Latest Developments
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Information
11.8.2 Bristol Myers Squibb OTC Drug Product Offered
11.8.3 Bristol Myers Squibb OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Bristol Myers Squibb Main Business Overview
11.8.5 Bristol Myers Squibb Latest Developments
11.9 Bukwang Pharmaceutica
11.9.1 Bukwang Pharmaceutica Company Information
11.9.2 Bukwang Pharmaceutica OTC Drug Product Offered
11.9.3 Bukwang Pharmaceutica OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Bukwang Pharmaceutica Main Business Overview
11.9.5 Bukwang Pharmaceutica Latest Developments
11.10 Chr. Hansen
11.10.1 Chr. Hansen Company Information
11.10.2 Chr. Hansen OTC Drug Product Offered
11.10.3 Chr. Hansen OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Chr. Hansen Main Business Overview
11.10.5 Chr. Hansen Latest Developments
11.11 Cipla
11.11.1 Cipla Company Information
11.11.2 Cipla OTC Drug Product Offered
11.11.3 Cipla OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Cipla Main Business Overview
11.11.5 Cipla Latest Developments
11.12 CoLucid
11.12.1 CoLucid Company Information
11.12.2 CoLucid OTC Drug Product Offered
11.12.3 CoLucid OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 CoLucid Main Business Overview
11.12.5 CoLucid Latest Developments
11.13 Daiichi Sankyo
11.13.1 Daiichi Sankyo Company Information
11.13.2 Daiichi Sankyo OTC Drug Product Offered
11.13.3 Daiichi Sankyo OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Daiichi Sankyo Main Business Overview
11.13.5 Daiichi Sankyo Latest Developments
11.14 Friggs
11.14.1 Friggs Company Information
11.14.2 Friggs OTC Drug Product Offered
11.14.3 Friggs OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Friggs Main Business Overview
11.14.5 Friggs Latest Developments
11.15 DSM
11.15.1 DSM Company Information
11.15.2 DSM OTC Drug Product Offered
11.15.3 DSM OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 DSM Main Business Overview
11.15.5 DSM Latest Developments
11.16 Eisai
11.16.1 Eisai Company Information
11.16.2 Eisai OTC Drug Product Offered
11.16.3 Eisai OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 Eisai Main Business Overview
11.16.5 Eisai Latest Developments
11.17 Eli Lilly
11.17.1 Eli Lilly Company Information
11.17.2 Eli Lilly OTC Drug Product Offered
11.17.3 Eli Lilly OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 Eli Lilly Main Business Overview
11.17.5 Eli Lilly Latest Developments
11.18 Herbalife
11.18.1 Herbalife Company Information
11.18.2 Herbalife OTC Drug Product Offered
11.18.3 Herbalife OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 Herbalife Main Business Overview
11.18.5 Herbalife Latest Developments
11.19 Euradite
11.19.1 Euradite Company Information
11.19.2 Euradite OTC Drug Product Offered
11.19.3 Euradite OTC Drug Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 Euradite Main Business Overview
11.19.5 Euradite Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.